The firms will continue to develop strains of algae that demonstrate improved photosynthetic efficiency and oil production.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
Cancer genomics firm Tempus' pact with Cleveland's UH Seidman Cancer Center adds to its list of partnerships with academic oncology centers.
As SpeeDx preps for the European launch of its STI tests, it will incorporate UgenTec's automated data analysis tool for PCR applications.
Objectives for this year include building a network of ELIXIR beacons, developing new features and security measures, and partnering with data owners.
Infoshield's encryption technology promises the ability to perform calculations and computations without having to first decrypt sensitive data.
As part of the deal, Helomics will promote MDNA's Prostate Core Mitomic Test and its liquid biopsy Prostate Mitomic Test in select US markets.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
The collaborations aim to combine Illumina's sequencing systems with Philips' IntelliSpace Genomics platform and with IBM's Watson for Genomics, respectively.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.